When Will Cutia Therapeutics (HKG:2487) Become Profitable?

Cutia Therapeutics (HKG:2487) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. With the latest financial year loss of CN¥434m and a trailing-twelve-month loss of CN¥472m, the HK$2.5b market-cap company amplified its loss by moving further away from its breakeven target. The most pressing concern for investors is Cutia Therapeutics' path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts’ expectations for the company.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

According to the 4 industry analysts covering Cutia Therapeutics, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2026, before generating positive profits of CN¥55m in 2027. Therefore, the company is expected to breakeven roughly 2 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 74%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

We're not going to go through company-specific developments for Cutia Therapeutics given that this is a high-level summary, but, bear in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Check out our latest analysis for Cutia Therapeutics

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 31% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of Cutia Therapeutics to cover in one brief article, but the key fundamentals for the company can all be found in one place – Cutia Therapeutics' company page on Simply Wall St. We've also compiled a list of key factors you should further research:

1. Valuation: What is Cutia Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Cutia Therapeutics is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Cutia Therapeutics’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.